DrugDashboards

Foundayo

orforglipron · ORFORGLIPRON CALCIUM 9 mg/1 · Tablet, Film Coated · Oral · Eli Lilly and Company

NDC 00002-4803-31 · 1 BOTTLE in 1 CARTON / 30 TABLET, FILM COATED in 1 BOTTLE · NDA · View full market →

The short version

Just 3 companies supply this market — thin enough that a single exit would be felt immediately.

The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.

Medicare Part D

No Medicare Part D plan in CMS's quarterly files lists this product. That usually means it is discontinued, a repackager's listing, or a product no plan has added to its formulary.

How Part D pricing works →

NADAC price per unit

No NADAC pricing on file for this NDC — NADAC covers drugs dispensed by retail community pharmacies.

Supply fragility

Not scored — fragility is computed for NADAC-priced NDCs.

90-day shortage risk (model v2)

0.1%chance of a new FDA shortage posting for orforglipron (oral solid) in the next 90 days

sole-source market

For scale: the typical drug’s chance is about 0.1% — this one is in ordinary territory.

Backtested statistical model over the whole market, not this package alone. Model details →

Regulatory

Application
NDA220934
TE code
—
Approval date
Apr 1, 2026
Patents / exclusivity
6 patents, 6 exclusivities
TypeNumber / codeExpires
exclusivityNCEApr 1, 2031
exclusivityNCEApr 1, 2031
exclusivityNCEApr 1, 2031
exclusivityNCEApr 1, 2031
exclusivityNCEApr 1, 2031
exclusivityNCEApr 1, 2031
patentRE50455Sep 26, 2037
patentRE50455Sep 26, 2037
patentRE50455Sep 26, 2037
patentRE50455Sep 26, 2037
patentRE50455Sep 26, 2037
patentRE50455Sep 26, 2037

Shortage history

No FDA shortage reports for this drug or its presentations.

Recalls (this NDC)

No enforcement reports list this package NDC.

Manufacturers of orforglipron (Tablet, Film Coated)

LabelerStrengthFirst seenLast seen
Eli Lilly and CompanyORFORGLIPRON CALCIUM 17.2 mg/1Jul 15, 2026Sep 2, 2026
Eli Lilly and CompanyORFORGLIPRON CALCIUM 14.5 mg/1Jul 15, 2026Sep 2, 2026
Eli Lilly and CompanyORFORGLIPRON CALCIUM 5.5 mg/1Jul 15, 2026Sep 2, 2026
Eli Lilly and CompanyORFORGLIPRON CALCIUM 2.5 mg/1Jul 15, 2026Sep 2, 2026
Eli Lilly and CompanyORFORGLIPRON CALCIUM .8 mg/1Jul 15, 2026Sep 2, 2026
Eli Lilly and CompanyORFORGLIPRON CALCIUM 9 mg/1Jul 15, 2026Sep 2, 2026
Lilly del Caribe, Inc.ORFORGLIPRON CALCIUM 9 mg/1Jul 15, 2026Sep 2, 2026
Lilly del Caribe, Inc.ORFORGLIPRON CALCIUM .8 mg/1Jul 15, 2026Sep 2, 2026
Lilly del Caribe, Inc.ORFORGLIPRON CALCIUM 14.5 mg/1Jul 15, 2026Sep 2, 2026
Lilly del Caribe, Inc.ORFORGLIPRON CALCIUM 17.2 mg/1Jul 15, 2026Sep 2, 2026
Lilly del Caribe, Inc.ORFORGLIPRON CALCIUM 2.5 mg/1Jul 15, 2026Sep 2, 2026
Lilly del Caribe, Inc.ORFORGLIPRON CALCIUM 5.5 mg/1Jul 15, 2026Sep 2, 2026
Pfizer Italia S.r.l.ORFORGLIPRON CALCIUM 5.5 mg/1Jul 15, 2026Sep 2, 2026
Pfizer Italia S.r.l.ORFORGLIPRON CALCIUM 17.2 mg/1Jul 15, 2026Sep 2, 2026
Pfizer Italia S.r.l.ORFORGLIPRON CALCIUM .8 mg/1Jul 15, 2026Sep 2, 2026
Pfizer Italia S.r.l.ORFORGLIPRON CALCIUM 14.5 mg/1Jul 15, 2026Sep 2, 2026
Pfizer Italia S.r.l.ORFORGLIPRON CALCIUM 2.5 mg/1Jul 15, 2026Sep 2, 2026

Roster from daily NDC Directory diffs — first/last seen dates start July 2026.

Cite this page

DrugDashboards, "Foundayo — NDC 00002-4803-31," retrieved September 3, 2026, https://drugdashboards.com/drug/00002480331.

Free to cite with attribution — see how the data is put together.